StreetAlpha.app
Home › Stocks › DFTX

Definium Therapeutics, Inc. (DFTX)

Healthcare
$28.34
▼ −3.87%
LAST CLOSE · NOV 20

Definium Therapeutics develops treatments based on psychedelic compounds for brain health disorders such as anxiety, depression and autism. It last closed at $28.34 on Nov 20, down 3.87% on the day. The next earnings report for DFTX is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, DFTX reported EPS of -$0.46. Over its last 8 reports the stock moved an average of 2.6% the session after earnings. Over the last 12 months DFTX insiders bought $0 of stock on the open market and sold $7.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is DFTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DFTX.

Key Stats

Last 12 months
Results
Net income
−$337.5M
EPS (diluted)
−$2.92
Valuation
Market cap
$3.9B
136.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$241.2M
At Sep 30
Debt
$36.7M
At Sep 30
Shareholder equity
$968.0M
Shares outstanding
136.9M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$93.0M−$93.0MFY2021FY2022: −$56.8M−$56.8MFY2022FY2023: −$95.7M−$95.7MFY2023FY2024: −$108.7M−$108.7MFY2024FY2025: −$183.8M−$183.8MFY2025

From DFTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.46
Quarter ended Sep 2026
Year ago EPS
-$0.78
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.42Dec '24Mar 2025: -$0.35Mar '25Jun 2025: -$0.50Jun '25Sep 2025: -$0.78Sep '25Dec 2025: -$0.50Dec '25Mar 2026: -$0.71Mar '26Jun 2026: -$1.44Jun '26Sep 2026: -$0.46Sep '26Latest -$0.46
Revenue by quarter
Not enough quarters on file yet.
How DFTX moved after its last 8 reports
Average move the session after a report ±2.6%
Nov 9, 2026After the close−2.1%
Aug 6, 2026After the close0.0%
May 7, 2026After the close−5.0%
Feb 26, 2026After the close+0.9%
Jan 12, 2026Time not announced+0.3%
Oct 29, 2025After the close+3.7%
Jul 31, 2025After the close−7.2%
May 8, 2025Time not announced−2.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DFTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DFTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DFTX

Technical Analysis

DFTX · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 17% below its 20 day and 24% below its 50 day average. It is 8% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot S1 at $27.84, and the nearest resistance the Pivot at $28.67.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.9%/day
Key levels
$49.7052 week high+75.4%
$39.15100 day average+38.1%
$35.97Swing high (Nov 10)+26.9%
$35.1850 day average+24.1%
$33.1720 day average+17.0%
$30.73200 day average+8.4%
$29.17Pivot R1+2.9%
$28.67Pivot+1.2%
$28.34Last close
$27.84Pivot S1−1.8%
$22.15Swing low (Jun 2)−21.8%
$10.4652 week low−63.1%
Indicators
RSI (14)33.72Weak, oversold below 30Neutral
MACD-1.77Below its signal lineBearish
Stochastic8.6Near the bottom of its rangeOversold
ADX (14)21.3Weak trend
Williams %R-97.9Oversold below −80, overbought above −20Oversold
CCI (20)-128.9Oversold below −100, overbought above 100Oversold
Rate of change−14.8%Change over 10 sessionsBearish
ATR (14)$1.96Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DFTX

What happened before

See how DFTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DFTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DFTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DFTXHow many large options trades hit DFTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

DFTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲199 buying vs 166 selling
  • ▲Held by funds +2.2 pts
  • ▼Funds holding -7
  • ▼Superinvestors: 0 added, 4 cut
  • ▲Put/call 0.22 to 0.19
Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding355362−1.9%
In funds' top 101013−23.1%
Held by funds86.1%83.9%+2.2 pts
New / increased62 / 137143 / 116−23.2%
Reduced / sold out97 / 6964 / 30+76.6%
Put/call ratio0.190.22−12.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DFTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DFTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$7.0M17 sales · 5 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $561K2026-03 sold $797K2026-06 sold $2.6M2026-09 sold $3.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 25Brandi RobertsCFOSale plan3,377$36.57$123K
Sep 25Mark SullivanChief Legal OfficerSale plan14,051$36.57$514K
Sep 25Matthew T. WileyChief Commercial OfficerSale plan3,097$36.57$113K
Sep 25Robert BarrowCEOSale plan31,550$36.57$1.2M
Sep 25Daniel KarlinChief Medical OfficerSale plan10,853$36.57$397K
Sep 3Robert BarrowCEOSale plan19,023$37.94$722K
Every insider buy and sale for DFTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DFTX insider trades →

From SEC Form 4 filings by DFTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DFTX is in one of them and how their past DFTX trades turned out.

DFTX in the AI portfolios
Loading…

DFTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DFTX in an article yet. Here's the latest on the wider market.

DFTX in the news

About Definium Therapeutics

Definium Therapeutics is a drug developer based in New York that is working on treatments for brain health conditions. Its main product candidates are derived from psychedelic and empathogen compounds. The lead candidate, DT120, is being tested in adults with generalized anxiety disorder and major depressive disorder, and a second candidate, DT402, is being studied in adults with autism spectrum disorder. None of its products are approved for sale yet, and the company is aiming to offer them to patients under medical care.

Headquarters
New York, NY